EUVIMEDEUVIMED entdecken
Leitlinie

Timing of Live-Attenuated Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologics: A Comparison of International Guidelines and Regulatory Labeling

Yohei Manabe, Hideharu Hagiya

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · 10.06.2026 · 52 (6) · 311-316

DOI: 10.5649/jjphcs.52.311 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), erschienen am 10.06.2026. Verfasst von Yohei Manabe und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adults with inflammatory bowel disease have an increased risk of infection, making vaccination against vaccine-preventable diseases essential. Live-attenuated vaccines should be avoided during immunosuppressive therapy. For biological agents, Japanese package inserts lack guidance on how long live vaccination should be avoided before and after treatment. Major guidelines and foreign regulatory labeling were reviewed. Recommendations were found in the Japanese expert consensus and guidance from the European Crohn’s and Colitis Organization, the British Society of Gastroenterology, and the American College of Gastroenterology. Most advised an interval of approximately 4 weeks between live-attenuated vaccination and the start of biological therapy and approximately 3 months between stopping biological therapy and live-attenuated vaccination. Some European Medicines Agency regulatory labeling of biologics suggested longer discontinuation intervals (12 – 21 weeks). Vedolizumab was an exception, with live-attenuated vaccination considered during therapy only when the benefits outweigh the risks. Given the limited evidence, clinical decision-making should integrate these recommendations with disease activity and vaccination urgency.

Zitieren

APA

Manabe, Y., & Hagiya, H. (2026). Timing of Live-Attenuated Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologics: A Comparison of International Guidelines and Regulatory Labeling. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 52(6), 311-316. https://doi.org/10.5649/jjphcs.52.311

Vancouver

Manabe Y, Hagiya H. Timing of Live-Attenuated Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologics: A Comparison of International Guidelines and Regulatory Labeling. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 2026;52(6):311-316. doi:10.5649/jjphcs.52.311

BibTeX
@article{Manabe2026,
  author = {Manabe, Yohei and Hagiya, Hideharu},
  title = {Timing of Live-Attenuated Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologics: A Comparison of International Guidelines and Regulatory Labeling},
  journal = {Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)},
  year = {2026},
  volume = {52},
  number = {6},
  pages = {311--316},
  doi = {10.5649/jjphcs.52.311}
}
Kostenlos starten →